Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting

Switching, manufacturing, and indication extrapolation among worries raised in closed-door session where AbbVie argued Humira's mechanism of action is not entirely understood.

With an advisory committee meeting on a potential Humira competitor only days away, AbbVie Inc. met privately with FDA to try and preserve its product's place in the market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Biosimilars & Generics